ACTRN12617000207314招募中未知
Quercetin as an augmentation agent in Treatment Resistant Schizophrenia”
niversity of Western Australia School of Medicine and Pharmacology0 个研究点目标入组 20 人开始时间: 2017年2月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Primary diagnosis of schizophrenia
- •Treatment resistant schizophrenia
- •Absence of centrally mediated side effects e.g. sedation, EPSE
- •Stable medications for 2 months
排除标准
- •Allergy to Quercetin or Quercetain (Registered Trademark)
- •Pregnancy or lactation
- •ongoing alcohol and substance abuse, brain damage or severe comorbid medical conditions that is likely to affect the CNS
- •Failure to respond to antipsychotic treatment because of non-adherence to treatment or intolerable side effects
- •Presence of a serious medical condition as defined as a disease that is likely to require an unplanned hospital admission for treatment in the period of the trial.
- •Use of medications which are likely to interact significantly with quercetin including: Digoxin, Verapamil, Cyclosporin, Topotecan, Quinidine, Raitanovir, Methotrexate, Dabigatran, Rivaroxaban. The Principal Investigator will evaluate the potential for interactions between quercetin and medications in the participant’s regimen.
研究者
相似试验
已完成
3 期
Effect of Quercetin supplementation on inflammatory and Creatinine kinase responses after a swimming session in girlsIRCT20200804048307N1Islamic Azad University20
尚未招募
1 期
sing a plant metabolite (quercetin) to optimise medication (mesalazine) metabolism to treat Primary Sclerosing Cholangitisinflammatory bowel diseaseOral and Gastrointestinal - Inflammatory bowel diseaseOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInflammatory and Immune System - Other inflammatory or immune system disordersulcerative colitisprimary sclerosing cholangitisACTRN12619001373167IBD Clinical Trials Unit, Mater Research Ltd.25
已完成
2 期
Quercetin in thalassemiabeta thalassemia major.Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia majorIRCT201701172709N43Vice chancellor for research, Iran University of Medical Sciences84
已完成
2 期
Quercetin on thalassemia induced depressioIRCT20091114002709N46Iran University of Medical Sciences84
已完成
不适用
Effect of co-administration of quercetin on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 *2 polymorphism: randomized crossover trialangina pectorisJPRN-UMIN000033639SOUSEIKAI Fukuoka Mirai Hospital, Clinical Research Center24